# Extended-Release Pain Medications Spektus and GEBRO Partner on Twice-Daily ActraFlex By Mursal Rahman | Written with AI assistance | Published 2026-11-04 | Business Source: Trend Hunter, https://www.trendhunter.com/trends/extended-release-pain-medications References: [prnewswire](https://www.prnewswire.com/news-releases/spektus-pharma-and-gebro-holding-announce-global-commercialization-partnership-for-actraflex-302927670.html)  Extended-release pain medications are advancing through a new partnership between Spektus Pharma and GEBRO Holding to commercialize ActraFlex. The formulation combines tramadol and paracetamol with Spektus' patented AmyloFlex technology, which is designed to release medication gradually and support a convenient twice-daily dosing schedule. ActraFlex builds on GEBRO's established Diliban product, combining an existing [pain management brand](https://www.trendhunter.com/trends/targeted-pain-relief) with a specialized drug-delivery system. The companies will pursue [regulatory approvals and manage distribution](https://www.trendhunter.com/trends/pharmaceutical-solution) across different international markets, drawing on their respective pharmaceutical networks. For Spektus, the agreement creates opportunities to expand its technology into additional markets throughout the Americas, Africa, and Asia. GEBRO will oversee commercialization in Europe and selected international territories, including Spain, where Diliban already has a commercial presence. The collaboration could strengthen both companies' pharmaceutical portfolios while expanding the potential reach of [sustained-release pain treatments](https://www.trendhunter.com/trends/precise-pain-relieving-patch). Image Credit: Spektus Pharma ## Trend Insights (Trend Hunter) - Score: 9.7/10 - Popularity: 92% | Activity: 100% | Freshness: 100% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America, Europe, Asia, Africa ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Business](https://www.trendhunter.com/business) > [Market](https://www.trendhunter.com/market) ## Key Themes ### What's Driving This Trend - **Extended-release Analgesics:** Longer-lasting pain formulations create space for differentiated therapies that improve adherence through reduced dosing frequency. - **Drug-delivery Partnerships:** Collaborations pairing established pharmaceutical brands with patented delivery platforms can accelerate global commercialization of reformulated medicines. - **Combination Pain Therapies:** Blended analgesic products offer new market potential by uniting familiar active ingredients with controlled-release performance. ### Who This Affects Most - **Pharmaceuticals:** Patent-backed formulation technologies provide pharmaceutical companies with portfolio expansion pathways beyond traditional new chemical entities. - **Pain Management:** Sustained-release medication formats are reshaping pain care by aligning therapeutic coverage with patient convenience. - **Healthcare Distribution:** International commercialization networks can turn regionally established treatments into broader opportunities across regulated global markets. ## Related on Trend Hunter - [Naproxen-Powered Pain Relief Medications](https://www.trendhunter.com/trends/tylenol-with-naproxen.md) - [Temperature-Changing Pain Creams](https://www.trendhunter.com/trends/tylenol-precise.md) - [Eu-Wide Biosimilar Drug Expansions](https://www.trendhunter.com/trends/biosimilar-drug.md) - [Bio-Optimized Pain Relivers](https://www.trendhunter.com/trends/relivaid.md) - [Integrated Prescription Support Services](https://www.trendhunter.com/trends/integrated-prescription-support-services.md) - [Non-Opioid Chronic Pain Treatments](https://www.trendhunter.com/trends/nonopioid-treatment.md) - [Targeted Rare Disease Therapies](https://www.trendhunter.com/trends/reduces-new-bone-growth.md) - [Combinational Pain Relief Tablets](https://www.trendhunter.com/trends/panacombo-dual-action-pain-relief.md) - [Real-World Tested Cannabinoids](https://www.trendhunter.com/trends/relief-protab-is-studied.md)